DE602007011592D1 - MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II - Google Patents

MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II

Info

Publication number
DE602007011592D1
DE602007011592D1 DE602007011592T DE602007011592T DE602007011592D1 DE 602007011592 D1 DE602007011592 D1 DE 602007011592D1 DE 602007011592 T DE602007011592 T DE 602007011592T DE 602007011592 T DE602007011592 T DE 602007011592T DE 602007011592 D1 DE602007011592 D1 DE 602007011592D1
Authority
DE
Germany
Prior art keywords
prognosis
diagnosis
medium
diabetes type
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007011592T
Other languages
German (de)
English (en)
Inventor
Bianca Bethan
Kristina Busch
Jan Wiemer
Martijn Gipmans
Edgar Leibold
Jochen Spranger
Thomas Bobbert
Andreas Friedrich Hermann Pfeiffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Metabolome Solutions GmbH
Original Assignee
Metanomics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06111705A external-priority patent/EP1837657A1/en
Application filed by Metanomics GmbH filed Critical Metanomics GmbH
Publication of DE602007011592D1 publication Critical patent/DE602007011592D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]
    • Y10T436/144444Glucose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602007011592T 2006-03-24 2007-03-21 MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II Active DE602007011592D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06111705A EP1837657A1 (en) 2006-03-24 2006-03-24 Means and method for predicting or diagnosing diabetes
EP06120273 2006-09-07
PCT/EP2007/052692 WO2007110358A2 (en) 2006-03-24 2007-03-21 Means and method for predicting diabetes

Publications (1)

Publication Number Publication Date
DE602007011592D1 true DE602007011592D1 (de) 2011-02-10

Family

ID=38016918

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602007011592T Active DE602007011592D1 (de) 2006-03-24 2007-03-21 MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II
DE602007011588T Active DE602007011588D1 (de) 2006-03-24 2007-03-21 MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES Typ II

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602007011588T Active DE602007011588D1 (de) 2006-03-24 2007-03-21 MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES Typ II

Country Status (10)

Country Link
US (2) US8216847B2 (zh)
EP (6) EP2008108B1 (zh)
JP (4) JP5167239B2 (zh)
CN (1) CN101438168B (zh)
AR (2) AR060121A1 (zh)
AT (2) ATE493660T1 (zh)
CA (2) CA2647122A1 (zh)
DE (2) DE602007011592D1 (zh)
ES (4) ES2525345T3 (zh)
WO (2) WO2007110358A2 (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2008108B1 (en) * 2006-03-24 2010-12-29 Metanomics GmbH MEANS AND METHOD FOR PREDICTING DIABETES type II
BRPI0815095B1 (pt) 2007-07-17 2021-04-13 Metabolon, Inc Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo
JPWO2009054350A1 (ja) * 2007-10-25 2011-03-03 味の素株式会社 耐糖能異常の評価方法、耐糖能異常評価装置、耐糖能異常評価方法、耐糖能異常評価システム、耐糖能異常評価プログラムおよび記録媒体、ならびに耐糖能異常の予防・改善物質の探索方法
BRPI0912175A2 (pt) * 2008-05-28 2015-10-06 Basf Se métodos para diagnosticar indução de enzima do fígado, para determinar se um composto é capaz de induzir indução de enzima do fígado em um indivíduo, e para identificar uma substância para tratar indução de enzima do fígado
US8597875B2 (en) 2008-05-28 2013-12-03 Basf Se Method for diagnosing liver toxicity with sex specific biomarkers
CN102105797A (zh) * 2008-05-28 2011-06-22 巴斯夫欧洲公司 用于评估过氧化物酶体增殖的工具和方法
JP2011528117A (ja) * 2008-07-15 2011-11-10 メタノミクス ヘルス ゲーエムベーハー 胃バイパス及びそれに関連する状態を診断する手段及び方法
DE102009013914B4 (de) * 2009-03-19 2011-05-05 Bruker Daltonik Gmbh Kalibriersubstanzen für Atmosphärendruck-Ionenquellen
US20120108668A1 (en) 2009-03-24 2012-05-03 Lundstedt Erik Torbjoern Metabolic profiles
US20120122243A1 (en) * 2009-06-04 2012-05-17 Charite Universitatsmedizin Berlin Means and method and means for diagnosing prostate carcinomas
WO2011018288A1 (en) * 2009-08-13 2011-02-17 Basf Se Means and methods for diagnosingthyroid disorders
US8367359B1 (en) * 2009-10-23 2013-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Metabolic biomarkers for diabetes and insulin resistance
ES2728120T3 (es) * 2010-01-29 2019-10-22 Metanomics Gmbh Medios y procedimientos para diagnosticar insuficiencia cardíaca en un sujeto
US20130126725A1 (en) * 2010-07-30 2013-05-23 Technische Universität Graz Analyses of Analytes by Mass Spectrometry with Values in at Least 3 Dimensions
WO2012051463A2 (en) * 2010-10-14 2012-04-19 The Regents Of The University Of California Urine metabolomic profile of diabetic kidney disease
US20130295692A1 (en) * 2010-12-23 2013-11-07 Metanomics Health Gmbh Means and methods for predicting diabetes
US20130101984A1 (en) * 2011-10-20 2013-04-25 The Washington University Methods of detecting sleepiness
US20150044702A1 (en) * 2012-03-09 2015-02-12 Basf Se Means and methods for assessing disorders related to impaired iron adsorption or energy metabolism
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
EP2867669B1 (en) 2012-06-27 2016-12-21 Metanomics Health GmbH Methods for identifying diabetes drugs
US20160047829A1 (en) 2012-10-18 2016-02-18 Ruprecht-Karls-Universität Heidelberg Means and Methods for Determining a Clearance Normalized Amount of a Metabolite Disease Biomarker in a Sample
EP2951313B1 (en) * 2013-01-31 2018-03-07 Metabolon, Inc. Biomarkers related to insulin resistance progression and methods using the same
KR102362357B1 (ko) * 2013-04-09 2022-02-15 아지노모토 가부시키가이샤 생활습관병 지표의 평가 방법, 생활습관병 지표 평가 장치, 생활습관병 지표 평가 방법, 생활습관병 지표 평가 프로그램, 생활습관병 지표 평가 시스템, 및 정보통신 단말장치
CN103616465A (zh) * 2013-10-28 2014-03-05 浙江大学 血液相关脂肪酸谱的建立方法
US20150323520A1 (en) * 2014-05-07 2015-11-12 The Trustees Of The Stevens Institute Of Technology Diagnosis of kidney transplant acute rejection
JP6773951B2 (ja) * 2014-05-30 2020-10-21 学校法人東京医科大学 唾液試料の調製方法
WO2016138232A1 (en) * 2015-02-26 2016-09-01 Wisconsin Alumni Research Foundation Methods for predicting glucoregulatory dysfunction
WO2017003166A1 (ko) * 2015-06-29 2017-01-05 고려대학교 산학협력단 대사체 분석을 이용한 당뇨병 조기 진단용 조성물
CN106979982B (zh) * 2016-01-19 2021-01-05 上海市第六人民医院 一种用于糖尿病风险预测、治疗评价的方法及试剂盒
CN105699663A (zh) * 2016-04-06 2016-06-22 深圳市老年医学研究所 2型糖尿病唾液蛋白指纹图谱分子诊断模型建立方法
CN105784829A (zh) * 2016-04-06 2016-07-20 深圳市老年医学研究所 2型糖尿病肾虚证唾液蛋白指纹图谱分子诊断模型建立方法
JP6609282B2 (ja) * 2016-05-17 2019-11-20 国立大学法人大阪大学 糖尿病を判定するための血液試料の分析方法及びシステム
JP2020512559A (ja) * 2017-03-31 2020-04-23 メタボロン,インコーポレイテッド 包括的および定量的な脂質およびトコフェロールの分析
JP7197555B2 (ja) * 2017-08-17 2022-12-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 思春期前の小児期前糖尿病のマーカー
CN108362804B (zh) * 2018-02-27 2019-01-29 山东英盛生物技术有限公司 一种检测血液样品中dha含量的方法及试剂盒
CN109507337B (zh) * 2018-12-29 2022-02-22 上海交通大学医学院附属新华医院 一种基于血尿中代谢产物预测甘地胶囊治疗糖尿病肾病机制的新方法
CN111443143B (zh) * 2020-04-30 2022-04-29 宁波市产品食品质量检验研究院(宁波市纤维检验所) 一种快速测定乳粉中胆固醇含量的方法
CN114216851A (zh) * 2020-11-27 2022-03-22 四川大学华西医院 一种基于表面增强拉曼光谱技术的急性胰腺炎评估装置
KR102583808B1 (ko) * 2021-03-05 2023-09-26 경희대학교 산학협력단 눈물을 이용한 당뇨병의 진단 방법 및 키트
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
CN114965753A (zh) * 2022-05-13 2022-08-30 重庆医科大学附属第一医院 一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540884A (en) 1982-12-29 1985-09-10 Finnigan Corporation Method of mass analyzing a sample by use of a quadrupole ion trap
AU590883B2 (en) * 1985-05-28 1989-11-23 Nippon Kayaku Kabushiki Kaisha Method of quantitative assay for 1,5-anhydroglucitol
JP2540349B2 (ja) * 1988-01-18 1996-10-02 日本化薬株式会社 腎性糖尿検査方法
ES2087165T3 (es) * 1989-11-30 1996-07-16 Croda Int Plc Uso de acido nervonico y de acidos grasos de cadenas largas en el tratamiento de las alteraciones provocadas por la desmielinizacion.
DE4242794A1 (en) * 1991-12-18 1993-06-24 Nitto Boseki Co Ltd Quantitative automated determn. of 1,5-anhydro:glucitol - using pyranose oxidase from Basidiomycetes fungi no.52
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US5397894A (en) 1993-05-28 1995-03-14 Varian Associates, Inc. Method of high mass resolution scanning of an ion trap mass spectrometer
JPH0870893A (ja) * 1994-09-02 1996-03-19 Nippon Kayaku Co Ltd 犬の糖尿病診断法、1,5−アンヒドログルシトールの定量法及びキット
JP3579549B2 (ja) * 1995-10-24 2004-10-20 株式会社トクヤマ 糖尿病または糖尿病合併症用マーカーとしての使用
EP0825258A4 (en) * 1996-02-20 2001-12-05 Kyowa Hakko Kogyo Kk METHOD FOR DETERMINING 1,5-ANHYDROGLUCITOL
US5965449A (en) * 1996-07-03 1999-10-12 Forbes Medi-Tech, Inc. Method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders
US5871949A (en) * 1996-12-04 1999-02-16 Daiichi Pure Chemicals Co., Ltd. Method of quantitative assay for 1,5-anhydroglucitol and reagent for quantitative assay
JP3129250B2 (ja) * 1997-09-10 2001-01-29 株式会社ミルス生命科学研究所 尿の化学分析方法
CA2291912A1 (en) * 1998-12-11 2000-06-11 Kyowa Medex Co., Ltd. Method and reagent for quantitative determination of 1,5-anhydroglucitol
US6518069B1 (en) * 1999-04-22 2003-02-11 Liposcience, Inc. Methods and computer program products for determining risk of developing type 2 diabetes and other insulin resistance related disorders
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
JP2001330599A (ja) * 2000-05-24 2001-11-30 Shimazu S D Kk Gc/msによる代謝異常スクリーニング診断装置
US20020068310A1 (en) * 2000-10-11 2002-06-06 Mihoko Sasaki Method and reagant for quantitative determination of 1,5-anhydroglucitol
ES2173049B1 (es) * 2001-03-28 2004-01-16 Oleoyl Estrone Developments S Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.
EP1417629B1 (en) * 2001-07-06 2008-02-20 Lipomics Technologies, Inc. Generating, viewing, interpreting, and utilizing a quantitative database of metabolites
WO2003027296A1 (fr) * 2001-09-20 2003-04-03 Plantech Research Institute Genes intervenant dans la synthese d'acide gras presentant une liaison double conjuguee trans-11-, cis-13-, et utilisation desdits genes
AU2002348574A1 (en) * 2001-09-24 2003-04-07 Lipomics Technologies, Inc. Methods of using quantitative lipid metabolome data
US7196323B2 (en) 2002-02-28 2007-03-27 Metanomics Gmbh & Co. Kgaa Mass spectrometry method for analyzing mixtures of substances
CA2477909A1 (en) * 2002-03-11 2003-09-25 Lipomics Technologies, Inc. Novel metabolic targets and markers
US20040132819A1 (en) * 2002-08-06 2004-07-08 Nancy Auestad Appetite control method
JP2004097134A (ja) * 2002-09-11 2004-04-02 Univ Hiroshima 鎖長延長酵素による長鎖脂肪酸の合成法
CA2527737A1 (en) * 2003-05-31 2004-12-09 Forbes Medi-Tech Inc. Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type iidiabetes
WO2005094200A2 (en) * 2003-06-20 2005-10-13 University Of Florida Biomarkers for differentiating between type 2 and type 2 diabetes
JP4066259B2 (ja) * 2003-09-11 2008-03-26 財団法人大阪産業振興機構 軟体動物由来廃棄物の処理方法
AU2005214925B8 (en) * 2004-02-17 2011-06-02 Bodybio Corporation Network and methods for integrating individualized clinical test results and nutritional treatment
US20050202521A1 (en) * 2004-03-10 2005-09-15 Albert Crum Methods of assessing the need for and the effectiveness of therapy with antioxidants
JP4799557B2 (ja) * 2004-06-09 2011-10-26 ベクトン・ディキンソン・アンド・カンパニー 多検体センサー
EP1776159A1 (en) * 2004-08-09 2007-04-25 Enzymotec Ltd. Food products for diabetics
JPWO2006073195A1 (ja) * 2005-01-07 2008-06-12 敏一 吉川 糖尿病の予知・診断方法および糖尿病予知・診断用キット
EP2008108B1 (en) * 2006-03-24 2010-12-29 Metanomics GmbH MEANS AND METHOD FOR PREDICTING DIABETES type II
BRPI0815095B1 (pt) * 2007-07-17 2021-04-13 Metabolon, Inc Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo

Also Published As

Publication number Publication date
JP2013076703A (ja) 2013-04-25
CN101438168A (zh) 2009-05-20
ATE493660T1 (de) 2011-01-15
EP2008108B1 (en) 2010-12-29
ATE493661T1 (de) 2011-01-15
EP2369346A2 (en) 2011-09-28
EP2005189A2 (en) 2008-12-24
US20100163720A1 (en) 2010-07-01
EP2339346A2 (en) 2011-06-29
JP2009530627A (ja) 2009-08-27
ES2522818T3 (es) 2014-11-18
JP5579819B2 (ja) 2014-08-27
CN101438168B (zh) 2013-10-16
ES2525345T3 (es) 2014-12-22
EP2005189B1 (en) 2010-12-29
AR060121A1 (es) 2008-05-28
CA2647122A1 (en) 2007-10-04
JP2013057672A (ja) 2013-03-28
CA2647197A1 (en) 2007-10-04
DE602007011588D1 (de) 2011-02-10
EP2336782A1 (en) 2011-06-22
US20100236321A1 (en) 2010-09-23
ES2522816T3 (es) 2014-11-18
EP2339346A3 (en) 2011-10-19
WO2007110358A2 (en) 2007-10-04
EP2330423B1 (en) 2014-10-01
EP2330423A1 (en) 2011-06-08
JP5167239B2 (ja) 2013-03-21
US8216847B2 (en) 2012-07-10
WO2007110357A2 (en) 2007-10-04
WO2007110357A3 (en) 2007-11-15
WO2007110358A3 (en) 2007-11-15
EP2008108A2 (en) 2008-12-31
EP2369346A3 (en) 2011-11-02
EP2336782B1 (en) 2014-08-27
ES2522815T3 (es) 2014-11-18
AR060120A1 (es) 2008-05-28
US8216848B2 (en) 2012-07-10
JP5199994B2 (ja) 2013-05-15
JP2009530626A (ja) 2009-08-27
EP2369346B1 (en) 2014-08-27
EP2339346B1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
DE602007011592D1 (de) MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II
DE112006000054A5 (de) Verfahren zur Diagnose eines Abgasnachbehandlungssystems
ATE500824T1 (de) Verfahren zur reinigung von trans-(-)-delta9- tetrahydrocannabinol und trans-(+)-delta9- tetrahydrocannabinol
DE602007005817D1 (de) System zur überwachung des katalysatorverschleisses und verfahren zur überwachung des katalysatorverschleisses
ATE530558T1 (de) Verfahren und verbindungen zur herstellung von natriumglucose-co-transporter-2-hemmern
DE602006020741D1 (de) Strommessschaltung und verfahren zur fehlerdiagnose darin
DE602005015473D1 (de) Verfahren und mittel zur herstellung von hyaluronan
BRPI0914801A2 (pt) método para detectar o grupo sanguíneo abo/rh/mn humano, e, kit
DE602007008174D1 (de) Verfahren und System zur Erkennung von Phishing
DE112005002742A5 (de) Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreasererkrankungen
DE602005007317D1 (de) Verfahren und System für Ultraschalluntersuchung
ATE479100T1 (de) Verfahren zur diagnose von lawsonia intracellularis
DE502006005961D1 (de) Endoskop und Verfahren zu seiner Herstellung
DE602006014106D1 (de) Verfahren zur diagnose von prostatakrebs
DE102007033255B8 (de) Einspritzeransteuerung und Ansteuerverfahren für dieselbe
EE200600031A (et) Aktiivelement, meetod aktiivelemendi saamiseks, aktiivelemendi kasutamine ekraanides ja pindades
DE502006005862D1 (de) Filterlage für einen, insbesondere konischen, wabenkörper zur abgasbehandlung und verfahren zur herstellung der filterlage
DE102008009718A8 (de) Verfahren und Mittel zur Enkodierung von Hintergrundrauschinformationen
DE60333195D1 (de) Verfahren zur diagnose des myokardinfarktrisikos
DE602004031104D1 (de) Informationsprozessor und Verfahren zur Multi-Hit Kontrolle
DE602008004112D1 (de) Verfahren und Vorrichtungen zur Erkennung von Fähigkeiten für medienunabhängige Übergabe
DE602005026107D1 (de) Verfahren zur aufreinigung von 2-chlor-5-chlormethyl-1,3-thiazol
DE602005003444D1 (de) Verfahren zur kostengünstigen Detektion von Ultrabreitbandpulsfolgen
DE112006000481A5 (de) Verfahren zur Bestimmung der elastischen Verformung von Bauteilen
DE112006001494A5 (de) System und Verfahren zur Überwachung konfektionierter vorgefertigter Speisen